Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Eli Lilly & Co (LLY) Receives a Buy from Morgan Stanley

Tipranks - Tipranks - Thu Apr 16, 6:31AM CDT

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Eli Lilly & Co today and set a price target of $1,327.00.

Claim 30% Off TipRanks

Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Johnson & Johnson, and Vertex Pharmaceuticals. According to TipRanks, Flynn has an average return of 9.0% and a 54.42% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $1,247.71 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Eli Lilly & Co’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $19.29 billion and a net profit of $6.64 billion. In comparison, last year the company earned a revenue of $13.53 billion and had a net profit of $4.41 billion

Read More on LLY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).